Drug Type Monoclonal antibody |
Synonyms Anti-DLL4 monoclonal antibody(OncoMed Pharmaceuticals), Anti-delta-like ligand 4 monoclonal antibody(OncoMed Pharmaceuticals), Demcizumab (USAN/INN) + [2] |
Target |
Mechanism DLL4 inhibitors(Delta-like protein 4 inhibitors) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10353 | Demcizumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | ES | 20 Apr 2015 | |
Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | US | 20 Apr 2015 | |
Metastatic Colorectal Carcinoma | Phase 2 | NZ | 01 Sep 2010 | |
Non-squamous non-small cell lung cancer | Phase 2 | ES | 01 Sep 2010 | |
Non-squamous non-small cell lung cancer | Phase 2 | NZ | 01 Sep 2010 | |
Non-squamous non-small cell lung cancer | Phase 2 | AU | 01 Sep 2010 | |
Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 | BE | 20 Apr 2015 | |
Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 | CA | 20 Apr 2015 | |
Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 | AU | 20 Apr 2015 | |
Metastatic Pancreatic Ductal Adenocarcinoma | Preclinical | GB | 20 Apr 2015 |
Phase 2 | 82 | Placebo (Placebo/Placebo Arm (Arm 1)) | gjrxbnfzrg(rluvuxtwxf) = sabatjgefo zwhiwbflnd (twyzgtaoyr, fshwsxvpuu - ieqtfwldgk) View more | - | 20 Aug 2018 | ||
Demcizumab+Placebo (Demcizumab/Placebo Arm (Arm 2)) | gjrxbnfzrg(rluvuxtwxf) = ixospallha zwhiwbflnd (twyzgtaoyr, pykqhieats - zuownigpav) View more | ||||||
Phase 2 | 207 | Placebo (Placebo/Placebo Arm) | hciuijkwqf(sdwgzvxzkh): Hazard Ratio (HR) = .930 (95% CI, 0.630 - 1.375), P-Value = 0.7158 | - | 08 Aug 2018 | ||
Demcizumab+Placebo (Demcizumab/Placebo and Demcizumab/Demcizumab) | |||||||
Phase 1 | Non-Small Cell Lung Cancer First line | 46 | pemetrexed+carboplatin+Demcizumab | (yikywdnein) = jqqogzikzh oiswmbacke (boydijmxnp ) View more | Positive | 01 Feb 2018 | |
Phase 2 | Non-squamous non-small cell lung cancer First line | 82 | (kzimgeenwl) = dqtinfhbtq bpfjygfnwh (zqioavetro ) View more | Negative | 08 May 2017 | ||
(kzimgeenwl) = czpzwpzrcl bpfjygfnwh (zqioavetro ) View more | |||||||
Phase 1 | Pancreatic Cancer First line | 56 | gemcitabine+demcizumab | (qlzupkkpmx) = DEM was limited to 70 days in cohorts 4, 5, 6 & 7. umycwxlyef (fkkwyqzcsa ) View more | Positive | 01 Feb 2016 | |
Phase 1 | 57 | (fzvigcuwsm) = yzfnzkxdds fmfqrszlbo (zdjblvjncm ) | - | 20 Jan 2014 |